Jefferies Upgrades Avanir Pharmaceuticals (AVNR) to Buy
Tweet
Share
E-mailGet Alerts AVNR Hot Sheet
Price: $16.96 --0%
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
4 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Jefferies upgraded Avanir Pharmaceuticals (NASDAQ: AVNR) from Hold to Buy with a price target of $17.00.
For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.
Shares of Avanir Pharmaceuticals closed at $6.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Upgrades Netflix (NFLX) to Buy, 'on Rev Upside from Tech Stack'
- Redburn-Atlantic Upgrades Shift4 Payments (FOUR) to Neutral Citing Balanced Risk/Reward Offering
- Wolfe Research Upgrades Bank of America (BAC) to Outperform, 'Underearning Firms Shouldn’t Trade at a Discount'
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
